The CARI Guidelines Caring for Australians with Renal Impairment. Blood urea sampling methods GUIDELINES

Similar documents
Dialysis Adequacy (HD) Guidelines

The CARI Guidelines Caring for Australians with Renal Impairment. Monitoring patients on peritoneal dialysis GUIDELINES

Dialysis Dose and Body Mass Index Are Strongly Associated with Survival in Hemodialysis Patients

There are no shortcuts to Dialysis

Guideline Recommendations

Risk factors for increased variability in dialysis delivery in haemodialysis patients

Evaluation and management of nutrition in children

GUIDELINE FOR HAEMODIALYSIS PRESCRIPTION FOR NEW PATIENTS COMMENCING HAEMODIALYSIS

Acceptance onto Dialysis Guidelines

[1] Levy [3] (odds ratio) 5.5. mannitol. (renal dose) dopamine 1 µg/kg/min atrial natriuretic peptide (ANP)

THE CURRENT PARADIGM of thrice-weekly

Hemodialysis is a life-sustaining procedure for the treatment of

The CARI Guidelines Caring for Australasians with Renal Impairment. Biochemical Targets. Calcium GUIDELINES

Chapter 7: Adequacy of Haemodialysis and Serum Bicarbonate

Chapter 6: Adequacy of haemodialysis (Urea reduction ratio)

The CARI Guidelines Caring for Australians with Renal Impairment. Cardiovascular Risk Factors

Nephrology Dialysis Transplantation

THE HEMODIALYSIS PRESCRIPTION: TREATMENT ADEQUACY GERALD SCHULMAN MD VANDERBILT UNIVERSITY MEDICAL SCHOOL NASHVILLE, TENNESSEE

mean hemoglobin 11 g/dl (110 g/l) compared to patients with lower mean hemoglobin values (Table 20).

St George Hospital Renal Department Internal Policy

The CARI Guidelines Caring for Australians with Renal Impairment. Mode of dialysis at initiation GUIDELINES

IN-CENTER HEMODIALYSIS (HD) CLINICAL PERFORMANCE MEASURES DATA COLLECTION FORM 2006

The Effect of High-Flux Hemodialysis on Dialysis-Associated Amyloidosis

Diacap. Constant performance resulting in high quality dialysis. Avitum

The CARI Guidelines Caring for Australians with Renal Impairment. Level of renal function at which to initiate dialysis GUIDELINES

The CARI Guidelines Caring for Australians with Renal Impairment. Other criteria for starting dialysis GUIDELINES

The measurement of blood access flow rate (Qa; ml/min)

WHEN (AND WHEN NOT) TO START DIALYSIS. Shahid Chandna, Ken Farrington

Objectives. Peritoneal Dialysis vs. Hemodialysis 02/27/2018. Peritoneal Dialysis Prescription and Adequacy Monitoring

Biochemical Analysis of End Stage Renal Disease Patients Following Regular Haemodialysis

Since its first application as a treatment for end-stage

Hemodialysis: Techniques and Prescription

Effect of the dialysis membrane on mortality of chronic

Complications observed in end-stage renal disease may be due to

EFFECT OF ONLINE HAEMODIAFILTRATION ON ALL- CAUSE MORTALITY AND CARDIOVASCULAR OUTCOMES Ercan Ok, Izmir, Turkey

St George Hospital Renal Department Guideline: INTERNAL ONLY ANTICOAGULATION - COMMENCEMENT OF HAEMODIALYSIS


IN-CENTER HEMODIALYSIS (HD) CLINICAL PERFORMANCE MEASURES DATA COLLECTION FORM 2001

New Zealand. Dialysis and Transplantation Audit

Associations of hemodialysis dose and session length with mortality risk in Australian and New Zealand patients

Solute clearances during continuous venovenous haemofiltration at various ultrafiltration flow rates using Multiflow-100 and HF1000 filters

Haemodialysis. Online Clearance Monitoring Assuring the Desired Dose of Dialysis

5. Comparison of continuous cyclic peritoneal dialysis (CCPD) with CAPD in treatment for patients with ESRD.

Nephrology Dialysis Transplantation

NKF-DOQI CLINICAL PRACTICE GUIDELINES FOR HEMODIALYSIS ADEQUACY

HEMODIALFILTRATION LITERATURE REVIEW AND PRACTICE CONSIDERATIONS 1.0 PRACTICE CONSIDERATIONS 2.0 CURRENT LITERATURE REVIEW

System Dynamics Highlights the Effect of Maintenance on Hemodialysis Performance

The CARI Guidelines Caring for Australasians with Renal Impairment. Serum phosphate GUIDELINES

The CARI Guidelines Caring for Australasians with Renal Impairment. Specific management of IgA nephropathy: role of tonsillectomy GUIDELINES

Prevalence of Access Recirculation in Prevalent Arterio-Venous (A-V) Fistula Hemodialysis Patients and Its Effect on Hemodialysis Adequacy

The CARI Guidelines Caring for Australasians with Renal Impairment. Membranous nephropathy role of steroids GUIDELINES

The CARI Guidelines Caring for Australians with Renal Impairment. 5. Classification of chronic kidney disease based on evaluation of kidney function

Haemodiafiltration - the case against. Prof Peter G Kerr Professor/Director of Nephrology Monash Health

Are Observational Studies Just as Effective as Randomized Clinical Trials?

Hemodiafiltration: principles and advantages over conventional HD. Rukshana Shroff Great Ormond Street Hospital for Children London, UK

Determinants of haemodialyser performance and the potential effect on clinical outcome

5. Indications for the use of urokinase in peritoneal dialysis associated peritonitis

CHAPTER 9. End Stage Kidney Disease in Aotearoa/New Zealand

Staff-Assisted Home Hemodialysis

HEMODIAFILTRATION PRINCIPLES AND ADVANTAGES OVER CONVENTIONAL HD PRESENTATION BY DR.ALI TAYEBI

Supplemental Quick Reference Guide

TREATMENT SAFETY AND EFFECTIVENESS CONTROL OF MODERN DIALYSIS MACHINES

Kidney Failure. Haemodialysis

COMPLETION DATE - 31-MAR-2011

OUT OF DATE. Choice of calcineurin inhibitors in adult renal transplantation: Effects on transplant outcomes

Lesson #7: Quality Assessment and Performance Improvement

Control of hyperphosphatemia is a major goal in patients

This guideline describes the care required for a patient receiving a red blood cell transfusion whilst undergoing extra corporeal therapies.

3/21/2017. Solute Clearance and Adequacy Targets in Peritoneal Dialysis. Peritoneal Membrane. Peritoneal Membrane

The CARI Guidelines Caring for Australasians with Renal Impairment. Specific management of IgA nephropathy: role of steroid therapy GUIDELINES

The CARI Guidelines Caring for Australasians with Renal Impairment. Specific management of IgA nephropathy: role of fish oil

The use of surrogates as key performance indicators

FOUR. Clinical Indicators of Care

Chapter 2. Prevalence of End Stage Kidney Disease. ANZDATA Registry 39th Annual Report. Data to 31-Dec-2015

CRRT for the Experience User 1. Claudio Ronco, M.D. David Selewski, M.D. Rolando Claure-Del Granado, M.D. AKI & CRRT Conference March, 2018

Principal Equations of Dialysis. John A. Sweeny

Phil. J. Internal Medicine, 47: 19-23, Jan.-Feb., 2009

Dialysis Adequacy and Kidney Disease Outcomes Quality Initiative Goals Achievement in an Iranian Hemodialysis Population

Hemodialysis Adequacy: A Complex and Evolving Paradigm. Balazs Szamosfalvi, MD Monday, 08/30/ :00-09:45

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors

2016 Annual Dialysis Conference Michelle Hofmann RN, BSN, CNN Renal Clinical Educator - Home

Karen Mak R.N. (Team Leader) Renal Dialysis Centre Hong Kong Sanatorium & Hospital

Dialysis Technicians Can Positively Influence Patient Outcomes

IN A STUDY that emphasizes the advantages

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors

Dialysis and Transplantation Audit

Confidence limits of arteriovenous fistula flow rate measured by the on-line thermodilution technique

Haemodialysis. The AutoFlow Function for the 5008 Therapy System Optimising the Dialysis Fluid Flow Rate

Effects of Hemodialyzer Reuse on Clearances of Urea and

CHAPTER 5. Haemodialysis. Kevan Polkinghorne Hannah Dent Aarti Gulyani Kylie Hurst Stephen McDonald

OUT OF DATE. Coronary artery, cerebrovascular and peripheral vascular disease

Treated ESRD Incidence Rate for Selected Countries, New Patients/Million Pop. 250 USA (All) USRDS 1996

Hemodiafiltration in Europe : Trends, Practices, Outcomes & Perspectives

Patients and Machines. NANT Annual National Symposium Wednesday March 9 th, 2011

Objectives. Pre-dialysis CKD: The Problem. Pre-dialysis CKD: The Problem. Objectives

Out of date SUGGESTIONS FOR CLINICAL CARE (Suggestions are based on level III and IV evidence)

Phosphate Management Guideline for Patients Receiving Extended Duration Hemodialysis

Transcription:

Date written: November 2004 Final submission: July 2005 Blood urea sampling methods GUIDELINES No recommendations possible based on Level I or II evidence SUGGESTIONS FOR CLINICAL CARE (Suggestions are based on Level III and IV evidence) Pre- and post-dialysis samples for urea measurement must be drawn at the same midweek treatment. The pre-dialysis sample should be drawn from the arterial needle without saline or heparin contamination. If there is a suggestion that the blood is contaminated, first withdraw 10 ml of blood before taking the sample (e.g. central venous catheter). It is suggested that the slow flow/stop pump sampling technique (described below) be used where possible to provide uniformity across dialysis units. The post-dialysis sample should be drawn from the arterial line port or arterial needle at 20 seconds after initiating slow (or zero) blood pump flow with attention to accuracy of timing (K/DOQI 2001, Guideline 8, Haemodialysis Adequacy). The 2 3 minute post-dialysis sampling practice is an acceptable alternative. Unit practice should be consistent, documented, and compared with standards with similar methodology. Pre-dialysis urea sampling: It is self-evident that sampling immediately before (not after) the commencement of dialysis is necessary to ensure valid dialysis dose estimates (Hakim 1998). Distorting factors for urea levels may be saline or heparin contamination of the sample, taken from the arterial needle or the central venous catheter limb. Post-dialysis urea sampling: Rapid post-dialysis blood urea level changes arise from rebound due to recirculation and regional blood flow distribution (ANZDATA 1998, Klinkmann & Davison 1994). The optimal time for sampling for single pool urea clearance estimates (30 50 minutes) is not practical in daily dialysis practice (Bloembergen et al 1999, Leypoldt et al 1999). Comparison of delivered dose with intended prescription requires adherence to methods used in studies forming the basis for these standards. Current practices are not uniform but comparison with the outcomes of the recent multicentre prospective randomised trial (the Hemodialysis

[HEMO] Study) warrants support for its carefully validated methodology (van Ypersele et al 1991, Hakim et al 1994). The ANZDATA post-dialysis sampling time recommendation has been 2 minutes after initiation of slow blood flow (ANZDATA survey form, 2003). This avoids the urea level dilution from any angio-access recirculation and from cardiopulmonary recirculation of dialysed blood directly from the heart to the dialysis access (without passage through the arteriovenous circulation to remove urea generated in the rest of the body). The HEMO study post-dialysis preferred sampling method involves withdrawal of blood 15 20 seconds after three steps: 1) initiating slow blood pump flow (50 100 ml/minute), 2) stopping dialysate flow (or setting at the slowest flow the machine will allow), and 3) turning the ultrafiltration rate to zero to minimise dialysis treatment effects. The angio-access recirculation rebound effect is at least partly removed but the cardiopulmonary recirculation effect is not, if the 20 second sampling technique is used (Koda et al 1997, Schwalbe et al 1997). This potentially results in slight overestimation of urea reduction rate (URR) or Kt/V. Sampling after 20 seconds will include unpredictable effects on rebound from cardiopulmonary recirculation and regional blood distribution, and hence underestimate urea clearance to an unknown and inconsistent degree. Nevertheless, this may work in the patient's favour by ensuring that the dose delivered is at least that calculated. Increased use of high efficiency/high flux dialysers of larger surface area and high blood flow rates delivering rapid urea clearance require the use of equilibrated Kt/V standards or of Kt/V and URR standards that recognise the inherent overestimation of single pool urea clearance arising from increased urea rebound with these techniques. Pre-dialysis sampling technique: The sample is drawn: a. directly from arterial needle before introduction of any saline or heparin or b. from central venous catheter after withdrawing at least 10 ml of blood. Post-dialysis sampling technique: Slow/stop pump techniques: a. decrease ultrafiltration rate (UFR) to zero, set lowest dialysate flow rate, turn blood flow to 50 100 ml/minute, and b. after 20 seconds draw sample from arterial port or stop pump after 20 seconds and draw sample from arterial needle or arterial port after clamping arterial and venous lines. An alternative technique is to withdraw a sample from the arterial port or needle after 2 minutes of slow flow. This results in a higher post-dialysis urea level with lower Kt/V values.

Background The provision of dialysis replaces many of the functions of the failing kidney. In an effort to ensure that treatment is optimised for individuals undergoing dialysis, some measure of dialysis efficacy is required. The most common measures currently in widespread use (URR and Kt/V) are discussed in another guideline and are derived by measuring changes in serum urea concentration over the course of a single dialysis session. Blood urea concentrations undergo rebound after a haemodialysis session, so it is vitally important that the method of measurement is clearly defined and reproducible. This will allow results within patients and populations of patients to be reliably compared. This guideline examined the available literature regarding different methods of sampling urea concentrations. Search strategy Databases searched: MeSH terms and text words for dialysis were combined with MeSH terms and text words for blood sampling and adequacy, and then combined with the Cochrane highly sensitive search strategy for randomised controlled trials. The search was carried out in Medline (1966 February Week 4 2004). The Cochrane Renal Group Trials Register was also searched for trials not indexed in Medline. Date of searches: 4 March 2004. What is the evidence? There are no trials examining the relationship between different methods of urea measurement and any clinical outcomes. The relationship between dialysis adequacy calculated from urea measurements and outcome is discussed in another guideline. What do the other guidelines say? Kidney Disease Outcomes Quality Initiative: 20-second sample after slowed blood pump flow (50 ml/minute or less) and ultrafiltration (UF) off and dialysate flow turned off (or at least to lowest setting). They do acknowledge the common practice of sampling after "run-back" or reinfusion of blood in dialysis circuit, which may be greater than 5 minutes after dialysis has been completed. (Guideline 8, Haemodialysis Adequacy) British Renal Association: 20-second sample recommended. (Appendix 2, pp. 35-36)

Canadian Society of Nephrology: As per K/DOQI guidelines. They acknowledge that if reliance is on URR, as opposed to formal urea kinetic modelling (UKM)-based Kt/V, the 2-minute technique may be preferable. (Guideline 4.3.6, Delivery of Hemodialysis) European Best Practice Guidelines: 20-second sample recommended. (Guideline I.4, Section I) International Guidelines: No recommendation. Implementation and audit An audit of dialysis centres in Australia and New Zealand would be useful in defining current practice. Standardisation of methodology between units would allow more direct comparisons to be made. Suggestions for future research No recommendation.

References ANZDATA survey form, 18 Nov 2003. Avaliable from: http://www.anzdata.org.au/forms/anzdatabackformnov2003.pdf. Bloembergen WE, Hakim RM, Stannard DC et al. Relationship of dialysis membrane and cause-specific mortality. Am J Kidney Dis 1999; 33: 1 10. Canadian Society of Nephrology Committee for Clinical Practice Guidelines. Clinical practice guidelines of the Canadian Society of Nephrology for treatment of patients with chronic renal failure. J Am Soc Nephrol 1999; 10(Suppl 13): S289 S321. Collins AJ, Ma JZ, Umen A et al. Urea index and other predictors of hemodialysis patient survival. Am J Kidney Dis 1994; 23: 272 82. European Best Practice Guidelines. Section I: Measurement of renal function, when to refer and when to start dialysis. Nephrol Dial Transplant 2002; 17(Suppl 7): S7 S15. Hakim RM. Influence of the dialysis membrane on outcome of ESRD patients. Am J Kidney Dis 1998; 32(Suppl 4): S71 S75. Hakim RM, Breyer J, Ismail N et al. Effects of dose of dialysis on morbidity and mortality. Am J Kidney Dis 1994; 23: 661 69. Kerr P. Method and location of dialysis; pp.115-116. ANZDATA Registry Report 1998. Australia and New Zealand Dialysis and Transplant Registry. Adelaide, South Australia. Klinkmann H, Davison AM. The biocompatibility puzzle partly solved, partly enigmatic. Nephrol Dial Transplant 1994; 9(Suppl 2): S184 S86. Koda Y, Nishi S, Miyazaki S et al. Switch from conventional to high-flux membrane reduces the risk of carpal tunnel syndrome and mortality of hemodialysis patients. Kidney Int 1997; 52: 1096 101. Leypoldt JK, Cheung AK, Carroll CE et al. Effect of dialysis membranes and middle molecule removal on chronic hemodialysis patient survival. Am J Kidney Dis 1999; 33: 349 55. NKF-K/DOQI Clinical Practice Guidelines for Hemodialysis Adequacy. New York, National Kidney Foundation, 2001; pp. 57 63. Owen WF Jr, Lew NL, Liu Y et al. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 1993; 329: 1001 06. Schwalbe S, Holzhauer M, Schaeffer J et al. Beta 2-microglobulin associated amyloidosis: a vanishing complication of long-term hemodialysis. Kidney Int 1997; 52: 1077 83.

The Renal Association and the Royal College of Physicians of London. Treatment of adults and children with renal failure. Standards and audit measures. 3 rd edition. London: The Lavenham Press Ltd, 2002. Van Ypersele de Strihou C, Jadoul M, Malghem J et al. Effect of dialysis membrane and patient s age on signs of dialysis-related amyloidosis. The Working Party on Dialysis Amyloidosis. Kidney Int 1991; 39: 1012 19.